EUCTR2009-011200-39-EE进行中（未招募）不适用
A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder.
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. The subject is male or female = 18 years of age and = 60 years.
- •To be eligible, female subjects must have a negative pregnancy test (i.e. serum beta hCG test) and be of:
- •a. Non-childbearing potential defined as pre-menopausal females with a documented
- •tubal ligation or hysterectomy; or postmenopausal defined as 12 months of
- •spontaneous amenorrhea [in questionable cases a blood sample with simultaneous
- •follicle stimulating hormone (FSH) > 40 MlU/ml and estradiol < 40 pg/ml (<140
- •pmol/L) is confirmatory]. Females on hormone replacement therapy (HRT) and
- •whose menopausal status is in doubt will be required to use one of the contraception methods in Section 8.1 if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of post-menopausal status prior to study enrollment. For most forms of HRT, at least 2-4 weeks will elapse between the cessation of therapy and the blood draw; this interval depends on the type and dosage of HRT. Following confirmation of their post-menopausal status, they can resume use of HRT during the study without use of a contraceptive method.
- •b. Child-bearing potential and agrees to use one of the contraception methods listed in Section 8.1 for an appropriate period of time (as determined by the product label or investigator) prior to the start of dosing to sufficiently minimize the risk of
- •pregnancy at that point. Female subjects must agree to use contraception until the
- •follow-up visit.
- •2. Male subjects must agree to use one of the contraception methods listed in
- •Section 8.1. This criterion must be followed from the time of the first dose of study
- •medication until the follow-up visit.
- •3. Body weight = 50 kg (110lbs) for males and = 45 kg (99lbs) for females.
- •4. Body mass index (BMI) within the range 18.5-35.0 kg/m2 inclusive.
- •5. The subject must have liver function (Alanine Aminotransferase [ALT], Aspartate
- •Aminotransferase [AST] and total bilirubin) and Alkaline Phosphatase (ALP) tests
- •within normal ranges at the Screening.
- •6. Subject must read and write at a level sufficient to understand and comply with the protocol requirements and complete study-related assessments.
- •7. Subjects must have the ability to comprehend the key components of the consent
- •form and must provide signed and dated written informed consent prior to admission
- •to the study.
- •8. Subject currently meets the diagnosis for MDD (without psychotic features), as
- •defined in the DSM-IV-TR, diagnosed with a comprehensive psychiatric evaluation
- •incorporating the MINI, as assessed* by a Board Certified psychiatrist.
- •*Assessment must include a face-to-face evaluation of the subject, but may be aided
- •by subject evaluation conducted by a healthcare professional with a clinically
- •relevant qualification (e.g., psychiatric nurse or psychologist) and a minimum of two
- •years of documented experience assessing subjects with MDD.
- •9. Subject must, in the investigator’s opinion based on clinical history, have met DSM
- •IV-TR criteria for their current major depressive episode for at least 4 weeks.
- •10 Subject must have had at least one previous major depressive episode with a
- •diagnosis of MDD in his/her history and is currently experiencing a recurrence of
- •11 Subjects must exhibit moderate to severe levels of depression as defined by:
- •IDS-SR when measured at the Screening and Randomization visits:
- •a total score =38, and
- •a score =1 for each of the items representing mood (item 5; feeling sad), interest
排除标准
- •1. History of excessive regular alcohol consumption within 3 months of the study defined as:
- •- For non-US sites: an average weekly intake of >21 units (or average daily intake >3 units) for males or >14 units (or average daily intake >2 units) for females. One unit is equivalent to 8 g of alcohol: a half-pint (~240 ml) of beer, 1 glass (125 ml) of wine or 1 (25 ml) measure of spirits.
- •- For US sites: an average weekly intake of >14 drinks (or average daily intake >2 drinks) for males or >7 drinks (or average daily intake >1 drink) for females. One drink is equivalent to 12 g of alcohol: 12 ounces (360 ml) of beer, 5 ounces (150 ml) of wine or 1.5 ounces (45 ml) of 80 proof distilled spirits
- •2. The subject has any history of liver disease.
- •3. A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening
- •4. The subject has a history of elevated liver function tests on more than one occasion (ALT, AST, and total bilirubin > 2 x ULN or ALP > 3 x ULN) in the past 7 months.
- •5. The subject has a significant cardiac, pulmonary, metabolic, renal, or gastrointestinal disease that, in the opinion of the investigator, places the subject at an unacceptable risk as a participant in this trial.
- •6. The subject has a history of autoimmune diseases.
- •7. The subject has any active infectious diseases, including active tuberculosis or a history of active tuberculosis.
- •8. The subject has a history of malignancy, except for surgically cured basal cell carcinoma or females with cured cervical carcinoma (> 2 yrs prior).
- •9. The subject has a history of HIV or other immunosuppressive disease.
- •10. The subject has uncontrolled diabetes.
- •11. The subject is pregnant or nursing.
- •12. Subject has a positive urine test at the Screening or Randomisation (Week 0) visits for illicit drug use with the exception of barbiturates see protocol for further information.
- •13. A history of DSM IV-TR diagnosis of substance abuse or dependence (other than nicotine) within the past 6 months.
- •14. Subject has: • Symptoms of the presenting illness which are better accounted for by another diagnosis*; or • A current DSM-IV-TR diagnosis of Panic Disorder; *view protocol for further information.
- •15. Subject has no contact with an adult on a daily basis (contact can be in person or via the telephone).
- •16. Subject has initiated psychotherapy within three months prior to the Screening visit, or plans to initiate psychotherapy during the trial. (View protocol for further information)
- •17. Subject has received electroconvulsive therapy or transcranial magnetic stimulation or vagal nerve stimulation within the six months prior to the Screening visit.
- •18. Subject, who, in the investigator’s judgment, poses a serious suicidal risk. View protocol for further information.
- •19. Subjects, who in the investigator's judgement, pose a significant homicidal risk or have ever been homicidal.
- •20. Subject has any laboratory abnormality that in the investigator’s judgement is considered to be clinically significant and could potentially affect subject safety or study outcome.
- •21. Subject has a current or past history of seizure (except for febrile seizures in childhood), or has a condition which, in the opinion of the investigator, predisposes the subject to seizures.
- •22. Subjects who are not euthyroid. View protocol for further information.
- •23. Women who have a positive serum (HCG) pregnancy test at the Screening visit, a positive urine pregnancy test at th
研究者
相似试验
进行中（未招募）
不适用
A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder.Major Depressive DisorderEUCTR2009-011200-39-BGGlaxoSmithKline Research & Development Ltd180
进行中（未招募）
不适用
A six week randomized, double-blind, multi-center, placebocontrolled, exploratory, adaptive design study to explore the antidepressant properties of the p38 MAP kinase inhibitor GW856553 compared to placebo in adult subjects with Major Depressive Disorder.MedDRA version: 12.0Level: LLTClassification code 10025453Term: Major depressive disorder NOSMajor Depressive DisorderEUCTR2009-011200-39-DEGlaxoSmithKline Research & Development Ltd180
进行中（未招募）
不适用
A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo withdrawal periodMedDRA version: 9.1Level: LLTClassification code 10020772Term: HypertensionHypertensionEUCTR2006-005261-19-FRovartis Pharma Services AG75
进行中（未招募）
不适用
A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo withdrawal periodHypertensionEUCTR2006-005261-19-SEovartis Pharma Services AG75
进行中（未招募）
不适用
A randomized, multicenter, double-blind, 6 week study to evaluate the dose response of valsartan on blood pressure reduction in children 1-5 years old with hypertension, followed by a 2 week placebo withdrawal periodHypertensionEUCTR2006-005261-19-HUovartis Pharma Services AG75